Evidence map›Paper›PMID 23815575›Full record

ArticleAIDS research and human retroviruses2013

Differential regulatory T cell activity in HIV type 1-exposed seronegative individuals.

Laura Pattacini, Pamela M Murnane, Erin M Kahle, Michael J Bolton, Jeffrey J Delrow, Jairam R Lingappa, Elly Katabira, Deborah Donnell, M Juliana McElrath, Jared M Baeten and 1 more

Registry-linked trialAbstract read
In one paragraph

Article in AIDS research and human retroviruses, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03701802 (Immunogenetic Modulators of Mucosal Protection From HIV-1), which is not on this map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03701802 completednot on this mapstarted 2018, after this paper: background citation

Immunogenetic Modulators of Mucosal Protection From HIV-1: The Kinga Study

TypeobservationalSponsorUniversity of WashingtonRan2018 to 2020Enrolled812ConditionsHIV Infections, HSV-2 Infection
3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Cell reports. Medicine · 2021
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Laura Pattacini1 Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center , Seattle, Washington.
Pamela M Murnane
Erin M Kahle
Michael J Bolton
Jeffrey J Delrow
Jairam R Lingappa
Elly Katabira
Deborah Donnell
M Juliana McElrath
Jared M Baeten
Jennifer M Lund

Funding

HIV-1 CELLULAR IMMUNITY IN EXPOSED SERONEGATIVESR01AI047086 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI MCELRATH, MARGARET JULIANA · 2000 to 2010
$4.5M
PrEP and protective immune responses against HIV-1R01AI096968 · NIAID · UNIVERSITY OF WASHINGTON · PI BAETEN, JARED, LUND, JENNIFER M · 2012 to 2015
$2.8M
Regulatory T cell Modulation of Immunity to Mucosal Viral InfectionsR01AI087657 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI LUND, JENNIFER M · 2010 to 2014
$2.2M
NIAID NIH HHS R01 AI047086NIAID NIH HHS R01 AI087657NIAID NIH HHS R01 AI096968PHS HHS NIAID/NIH 1R01AI096968PHS HHS NIAID/NIH 3 R01AI047086-10S1
6 · The paper itself

Abstract

The potential role of conventional and regulatory T cells (Tregs) in protection from HIV-1 infection remains unclear. To address this question, we analyzed samples from 129 HIV-1-exposed seronegative individuals (HESN) from an HIV-1-serodiscordant couples cohort. To assess the presence of HIV-specific T cell responses and Treg function, we measured the proliferation of T cells in response to HIV-1 peptide pools in peripheral blood mononuclear cells (PBMCs) and PBMCs depleted of Tregs. We identified HIV-specific CD4(+) and CD8(+) T cell responses and, surprisingly, the overall CD4(+) and CD8(+) T cell response rate was not increased when Tregs were removed from cell preparations. Of the 20 individuals that had HIV-1-specific CD4(+) T cell responses, only eight had Tregs that could suppress this proliferation. When compared with individuals whose Tregs could suppress HIV-1-specific CD4(+) T cell proliferation, individuals with Tregs unable to suppress showed a trend toward increased T cell activation and Treg frequency and a significant increase in HIV-1-specific production of microphage inflammatory protein-1β (MIP-1β) by CD4(+) T cells, autocrine production of which has been shown to be protective in terms of HIV-1 infection of CD4(+) T cells.

Indexed as

AdultCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCell ProliferationChemokine CCL4FemaleHIV-1HumansLeukocytes, MononuclearMaleT-Lymphocytes, RegulatoryT-Lymphocyte SubsetsCCL4 protein, humanChemokine CCL4

Identifiers

PMID23815575
PMCPMC3785803

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.